ReviewClinical pharmacokinetics2020
Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics.
Review in Clinical pharmacokinetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis.BMC infectious diseases · 2025Pooled it
- Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials.BMC infectious diseases · 2024Pooled it
- Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.Clinical pharmacokinetics · 2024Trial
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Efficacy and Safety of Tetracyclines in Bone and Joint Infections: A Literature Review.Infectious diseases and therapy · 2026Review
- Efficacy and short-term safety of intravenous omadacycline as second-line therapy for macrolide- unresponsive Mycoplasma pneumoniae pneumonia in children: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Efficacy, Safety, and in vitro Sensitivity of Omadacycline in the Treatment of Brucellosis: A Case Series Study.Infection and drug resistance · 2026Article
- Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance.Drugs in R&D · 2025Review
- Chlamydia psittacosis infection complicating cerebral infarction: A case report and literature review.Medicine · 2025Review
- Compassionate Use of Omadacycline in a Down Syndrome Pre-Schooler With Critically Ill Atypical Pneumonia Caused by Macrolide-Resistant Mycoplasma Pneumoniae.Infection and drug resistance · 2025Article
- Unveiling the therapeutic potential of caudatin: Structural optimization, pharmacological mechanisms, and therapeutic implications.Frontiers in pharmacology · 2025Review
- Omadacycline for the Treatment of SevereInternational medical case reports journal · 2025Article
- Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential.Biomolecules · 2024Review
- Article
- The in vitro Activity of Omadacycline Alone and in Combination Against Carbapenem-ResistantInfection and drug resistance · 2024Article
- Salivary Proteins and Metabolites as Caries Biomarkers in Adolescents.Caries research · 2024Article
- Omadacycline for the treatment of patients withFrontiers in microbiology · 2024Article
- Case Report of SevereInternational medical case reports journal · 2024Article
- Omadacycline for the treatment of severe pneumonia caused byFrontiers in medicine · 2023Article
- Case Report: Omadacycline in the treatment of macrolide-unresponsiveFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omadacycline is a novel aminomethylcycline antibiotic (antibacterial). Omadacycline has had chemical structure modifications at the C9 and C7 positions of the core tetracycline rings that allow stability in the efflux pump and ribosomal protection protein mechanisms of tetracycline resistance. The systemic exposure (i.e., maximum plasma concentrations [C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.